ikenaoncology.com - IMA Net Assets per Single Share

Public company logo of Ikena Oncology, Inc. (IMA)

ImageneBio Inc is creating an advanced R&D platform to develop drugs that suppress the metabolism of neoplasms. The book value per share metric illustrates capital dynamics, where the 12.56 level indicates the state of the parameter. The company strictly adheres to ESG standards, minimizing harmful laboratory emissions. Meanwhile, business success relies on clinical trial results, supported by a sufficient cash reserve.

Accounting Value of a Share: Ikena Oncology, Inc. (IMA) for 07/29/2025 - 10/27/2026

ImageneBio - analytical breakdowns and key metrics (IMA)

- price and consensus price forecast:
Stock Price Ikena Oncology, Inc.|IMA - Analyst Consensus Forecast
- market capitalization data:
Market Value ImageneBio Inc|IMA - Full Business Value
- book capitalization data:
Book Value per Share Ikena Oncology|IMA - Accounting Value of Company|Market Capitalization to Book Value Ratio ikenaoncology.com|IMA - Company Total Assets
- debt and liquidity data:
Debt to Equity ImageneBio Inc|IMA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ikena Oncology, Inc.|IMA - Company Total Debt|Debts to Book Capitalization ImageneBio Inc
Analysis of all company metrics:ikenaoncology.com (IMA)
Signature product of Ikena Oncology, Inc.

For ImageneBio Inc (IMA), whose valuation depends on clinical trial outcomes and patent protection, the lack of pricing power makes assets the key basis for valuation. The BVPS trend reflects the net asset value per share, allowing investors to track the business's intrinsic capitalization; steady BVPS growth signals financial stability, whereas stagnation may indicate a risk of overpaying for the asset.

Competitor analysis

Argenx - Book Value per Share|BNTX: Book Value per Share|Net Assets per Single Share Abivax Corp (ABVX)|admabiologics.com (ADMA) - Share Book Value|PTGX - Book Value per Share|Accounting Value of a Share Immunovant Inc|Book Value per Share KNSA|Book Value per Share GRFS (Grifols Biemat)|Net Assets per Single Share Adaptive Biotechnologies|celldex.com - Accounting Value of a Share|AUPH: Net Assets per Single Share|BCRX - Accounting Value per Share|VERA: Book Value per Share|Book Value per Share Dianthus Corp|PHVS - Accounting Value per Share|Accounting Value of a Share AbCellera Corp|TRML (Tourmaline Bio) - Book Value per Share|Net Assets per Share PGEN (Precigen Inc)|Pharming - Net Assets per Single Share|Nektar Corp - Accounting Value per Share|UPB: Net Assets per Single Share|zenasbio.com (ZBIO) - Accounting Value per Share|IMNM: Accounting Value per Share|GOSS (Gossamer Bio Inc) - Book Value per Share|Net Assets per Single Share KalVista Pharmaceuticals Inc (KALV)|Equity per Share Septerna Pharma|Pieris Pharmaceuticals - Book Value per Share|Net Asset Value per Share savarapharma.com (SVRA)|Book Value per Share RIGL|AnaptysBio Inc - Net Assets per Share|ATXS: Net Assets per Single Share|ENGN - Accounting Value per Share|RAPT: Book Value per Share|Aerovate Therapeutics (JBIO) - Book Value per Share|Aclaris Therapeutics, Inc. - Book Value per Share|Book Value of One Share Kyverna Therapeutics Inc.|Tiziana Life Sciences PLC - Book Value per Share|Net Asset Value per Share CABA (Cabaletta Bio Inc)|VTYX - Net Assets per Single Share|Equity per Share theratech.com THTX|AVTX (Avalo Therapeutics) - Book Value per Share|ELDN - Net Asset Value per Share|Agenus Inc (AGEN) - Book Value per Share|Climb Bio, Inc (CLYM) - Net Assets per Single Share|ZURA: Book Value per Share|Net Assets per Share ATYR|Adagene - Net Assets per Single Share|Net Asset Value per Share shattucklabs.com STTK|Accounting Value per Share Equillium|Accounting Value of a Share Connect Biopharma Holdings CNTB|Book Value per Share IMUX (Immunic Inc)|ATRA: Net Assets per Share|Net Assets per Single Share inflarx.de|X4 Pharmaceuticals Inc. (XFOR) - Equity per Share|Book Value per Share ACET|Accounting Value per Share Celularity Corp|INMB (INmune Bio, Inc.) - Book Value per Share|Net Assets per Share BRNS (barinthusbio.com)|Kezar Life Sciences, Inc. - Net Assets per Single Share|Accounting Value per Share SAB Biotherapeutics Inc. SABS|Akari Therapeutics plc - Book Value per Share|ENLV: Book Value per Share|Net Assets per Single Share q32bio.com (QTTB)|geovax.com (GOVX) - Share Book Value|EDSA - Book Value per Share|Accounting Value of a Share iBio Inc|Book Value per Share CARM|Book Value per Share XTLB (XTL Bio)|Net Assets per Single Share Bolt Biotherapeutics, Inc.|HCW Biologics, Inc. - Accounting Value of a Share|APVO: Net Assets per Single Share|AIM - Accounting Value per Share|ADTX: Book Value per Share|Book Value per Share GRI Bio Corporation|XRTX - Accounting Value per Share|Accounting Value of a Share reshapelifesciences.com|REVB (Revelation Biosciences, Inc.) - Book Value per Share|Net Assets per Share INDP (Indaptus Therapeutics Inc)|Scinai - Net Assets per Single Share|CalciMedica Inc - Accounting Value per Share|AFMD: Net Assets per Single Share|Allakos Inc. (ALLK) - Accounting Value per Share|HOOK: Accounting Value per Share|IGMS (IGM Biosciences) - Book Value per Share|Net Assets per Single Share iTeos (ITOS)|Equity per Share Ocean Biomedical Corp|TC Biopharm - Book Value per Share|Net Asset Value per Share thirdharmonicbio.com (THRD)